Compounding pharmacies create customized medications tailored to individual patient needs, filling a critical gap where commercial drug formulations are unavailable, inappropriate, or unaffordable. The industry operates under a dual regulatory framework involving state pharmacy boards and increasing FDA oversight, particularly for sterile preparations, creating meaningful barriers to entry. Demand is driven by aging demographics, growth in hormone replacement therapy, veterinary medicine, and specialty pain management, making the sector both resilient and attractive to healthcare-focused acquirers.
Who buys these: Licensed pharmacists seeking ownership, private equity groups targeting specialty healthcare, strategic acquirers such as pharmacy chains or healthcare networks, and entrepreneurial investors with pharmacy or healthcare operations backgrounds
3.5–6×
Typical EBITDA multiple
$1M–$5M
Revenue range
Growing
Market trend
SBA Eligible
7(a) financing available
Recession Resistant
Essential service
Minimum $500K SDE or $1M+ revenue; licensed and accredited facility (PCAB preferred); clean regulatory history with no FDA 483 observations; diversified prescriber base; documented SOPs for compounding processes; buyer must hold or obtain pharmacist-in-charge licensure
Get Deal Flow In Your Inbox
New Compounding Pharmacy acquisition targets delivered weekly — free to join.
Key items to investigate when evaluating a Compounding Pharmacy acquisition
Seller Intelligence
Who sells Compounding Pharmacy businesses?
Pharmacist-owners approaching retirement, founders seeking liquidity after building a niche compounding practice, owners facing regulatory fatigue or capital constraints for facility upgrades, and multi-location pharmacy operators looking to divest a single compounding unit
Typical exit timeline: 12–24 months
Compounding Pharmacy businesses in the $1M–$5M revenue range typically sell for 3.5–6× EBITDA. Minimum $500K SDE or $1M+ revenue; licensed and accredited facility (PCAB preferred); clean regulatory history with no FDA 483 observations; diversified prescriber base; documented SOPs for compounding processes; buyer must hold or obtain pharmacist-in-charge licensure
Compounding Pharmacy businesses typically trade at 3.5–6× EBITDA in the lower middle market. The market is highly fragmented with growing demand, which supports premium multiples.
Compounding Pharmacy businesses are SBA 7(a) eligible, making them accessible to first-time buyers. Full asset acquisition with SBA 7(a) financing, seller note of 10–15%, and earnout tied to prescriber retention
Key due diligence areas include: State pharmacy board license status and history of any disciplinary actions or warnings; USP 795, 797, and 800 compliance documentation including beyond-use dating policies and cleanroom certifications; Prescriber referral concentration and transferability of key physician relationships; Revenue mix between sterile and non-sterile formulations and top compound categories; Payer mix analysis including cash-pay vs. insurance reimbursement and any third-party audit exposure.
Related Searches
DealFlow OS surfaces acquisition targets, scores seller motivation, and generates outreach — all in one place.
Start finding deals — freeNo credit card required
For Buyers
For Sellers